Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

What is claimed is:

1. (Previously Presented) A method of promoting oligodendrocyte survival in a human suffering from stroke which comprises administering to said human a therapeutically effective amount of an anti-MAG antibody or a functional fragment thereof.

2. (Cancelled)

3. (Previously Presented) A method according to claim 1 wherein the anti-MAG antibody is an altered antibody.

4. (Previously Presented) A method according to claim 1 wherein the anti-MAG antibody is a chimeric antibody.

5. (Previously Presented) A method according to claim 1 wherein the anti-MAG antibody is a humanised antibody.

6. (Currently Amended) A method of promoting oligodendrocyte survival in a human suffering from stroke, which comprises administering to said human a therapeutically effective amount of an altered anti-MAG antibody or functional fragment thereof, wherein the altered antibody or functional fragment thereof binds to MAG and comprises one or more of the following complementarity determining regions (CDRs) selected from the group consisting of: CDRL1 (SEQ ID NO: 1), CDRL2 (SEQ ID NO: 2), CDRL3 (SEQ ID NO: 3), CDRH1 (SEQ ID NO: 4), CDRH2 (SEQ ID NO: 5), and CDRH3 (SEQ ID NO: 6).

~~Light chain CDRs~~

~~CDR~~	***~~According to Kabat~~***
~~L1~~	~~KSSHSVLYSSNQKNYLA~~
~~L2~~	~~WASTRES~~

~~L3~~	~~HQYLSSLT~~

~~Heavy chain CDRs~~

~~CDR~~	***~~According to Kabat~~***
~~H1~~	~~NYGMN~~
~~H2~~	~~WINTYTGEPTYADDFTG~~
~~H3~~	~~NPINYYGINYEGYVMDY~~

7. (Currently Amended) A method according to claim 6 wherein the altered antibody or functional fragment thereof comprises (a) a heavy chain variable domain which comprises one or more ~~CDR's~~CDRs selected from ~~CDRH1, CDRH2 and CDRH3~~ the group consisting of: CDRH1 (SEQ ID NO: 4), CDRH2 (SEQ ID NO: 5), and CDRH3 (SEQ ID NO: 6) and (b) a light chain variable domain which comprises one or more CDRs selected from the group consisting of: CDRL1 (SEQ ID NO: 1), CDRL2 (SEQ ID NO: 2), and CDRL3 (SEQ ID NO: 3)~~CDRL1, CDRL2 and CDRL3~~.

8. (Currently Amended) A method according to claim 7 wherein the altered anti-MAG antibody or functional fragment thereof comprises ~~a variable domain selected from~~ :

a heavy chain variable domain (V_H) which comprises in sequence hypervariable regions ~~CDRH1, CDRH2 and CDRH3~~ CDRH1 (SEQ ID NO: 4), CDRH2 (SEQ ID NO: 5), and CDRH3 (SEQ ID NO: 6)

and

a light chain variable domain (V_L) which comprises in sequence hypervariable regions ~~CDRL1, CDRL2 and CDRL3~~ CDRL1 (SEQ ID NO: 1), CDRL2 (SEQ ID NO: 2), and CDRL3 (SEQ ID NO: 3).

9. (Currently Amended) A method according to claim 8 wherein the altered anti-MAG antibody or functional fragment thereof comprises at least one variable domain selected from the group consisting of:[[of]] a heavy chain of SEQ ID NO: 7, a heavy chain of SEQ ID NO: [[8]]9, and a light chain of SEQ ID NO:[[9]]8.

10. (Currently Amended) A method according to claim 8 wherein the altered anti-MAG antibody or functional fragment thereof comprises at least one ~~of a~~ heavy chain variable region selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13 and a light chain variable region selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

11. (Currently Amended) A method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 10 and a light chain variable region comprising a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

12. (Currently Amended) A method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 11 and a light chain variable region comprising a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

13. (Currently Amended) A method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

14. (Currently Amended) A method according to claim 10 wherein the altered anti-MAG antibody is a humanized antibody and comprises (a) a heavy chain variable fragment comprising SEQ ID NO: 10, ~~11 or 12,~~SEQ ID NO: 11, or SEQ ID NO: 12, (b) a constant part of a human heavy chain or fragment thereof, (c) a light chain variable fragment comprising SEQ ID NO: 14, ~~15, 16, or 17~~ SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17 and (d) a constant part of a human light chain.

15. (Previously Presented) A method according to claim 14 wherein the humanized antibody is class IgG.

16. (Previously Presented) A method according to claim 15 wherein the humanized antibody is class IgG1.

17. (Currently Amended) A method according to claim 16 wherein the antibody heavy chain is: SEQ ID NO: 18.
~~MGWSCIILFLVATATGVHSQVQLVQSGSELKKPGASVKVSCKASGYTF TNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDT SVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK~~ (SEQ ID NO: 18).

18. (Currently Amended) A method according to claim 16 wherein the antibody light chain is: (SEQ ID NO: 19).
~~MGWSCIILFLVATATGVHSDIVMTQSPDSLAVSLGERATINCKSSHSVL YSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD FTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 19).~~

19. (Previously Presented) A method of promoting oligodendrocyte survival in a human suffering from stroke, which comprises administering to said human a therapeutically effective amount of an altered anti-MAG antibody or functional fragment thereof, wherein the antibody is an antibody which binds to the same epitope as the antibody having the CDRs of claim 6.